RAPT Therapeutics, Inc. (RAPT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Unrealized loss on marketable securities | -19 | -15 | 154 | |
| Research and development | 12,340 | 12,042 | 13,340 | |
| General and administrative | 7,195 | 7,223 | 6,448 | |
| Total operating expenses | 19,535 | 19,265 | 19,788 | |
| Loss from operations | -19,535 | -19,265 | -19,788 | |
| Other income, net | 1,892 | 2,100 | 1,356 | |
| Net loss | -17,643 | -17,165 | -18,432 | |
| Total comprehensive loss | -17,662 | -17,180 | -18,278 | |
| Net loss per share, basic | -0.65 | -0.08 | -0.47 | |
| Net loss per share, diluted | -0.65 | -0.08 | -0.47 | |
| Weighted-average shares used to compute net loss per share, basic | 26,949,752 | 215,410,253 | 38,903,476 | |
| Weighted-average shares used to compute net loss per share, diluted | 26,949,752 | 215,410,253 | 38,903,476 | |